Cyclin-dependent kinase 12 (CDK12) is an attractive therapeutic target due to its critical role in transcriptional regulation and DNA damage response and is frequently co-amplified with ERBB2 (HER2) in breast cancer. CDK12 forms an active complex with its obligate partner cyclin K (CCNK), and…
Leading prostate cancer expert Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, to discuss unmet needs in metastatic castration-resistant prostate cancer (mCRPC) and the potential for therapies beyond PSMA Webinar on December 1, 2026, at 8:00 a.m. ET to review recently...
RADIANZ results will inform ATNM-400 clinical development beyond prostate cancer to patients with advanced HER3-expressing solid tumors in multiple cancers Builds on initial first-in-human clinical data in metastatic castration-resistant prostate cancer presented at EANM 2026 and featured...
Background The combination of PD-1 blockade, HER2-targeted therapy and chemotherapy improves outcomes in HER2-positive advanced gastric and gastro-oesophageal junction adenocarcinoma. However, chemotherapy can independently alter the tumour microenvironment, making the biological effects of PD-1…
